Infectious Disease Molecular Diagnostics Market Worth $40.8 Billion By 2028

September 2021 | Report Format: Electronic (PDF)

Infectious Disease Molecular Diagnostics Market Growth & Trends

The global infectious disease molecular diagnostics market size is expected to reach USD 40.8 billion by 2028, according to a new report by Grand View Research, Inc. The market is estimated to expand at a CAGR of 3.0% from 2020 to 2028. The market is driven by the introduction of technologically advanced products and an increase in demand for molecular diagnostics in PoC settings.

Rapid technological advancements with portability, accurate results, and cost-effectiveness are anticipated to serve as crucial drivers of the market for infectious disease molecular diagnostics. Companies are upgrading their products by implementing new techniques to gain specific and accurate results. Key players are updating their product portfolio for PCR instruments with increased R&D initiatives for developing novel kits to target emerging diseases or by entering into agreements with other kit manufacturing companies.

Technologies such as INAAT, mass spectroscopy, and ISH are advanced and have a low false-positive rate as compared to other traditional diagnostic tests. Advantages such as the cost-effectiveness and user-friendliness of this technology and the accuracy offered are estimated to increase the adoption of this technology.

The use of molecular diagnostics in research institutes is increasing. The use of techniques such as PCR, western blotting, and southern blotting is becoming common. Moreover, the spread of SARS-CoV-2 infection globally has led to an increase in research funding by governments as well as diagnostic companies to search for innovative molecular diagnostics.

Molecular diagnostics deliver effective and accurate results. Moreover, these tests enable the early detection of diseases, maintaining a low threat of substitutes. However, the high prices of these tests are expected to encourage patients to shift to external substitutes. Moreover, for the detection of newer infections such as SARS-CoV-2, the rate of internal substitution is high, which boosts competitive rivalry.

key Request a free sample copy or view report summary: Infectious Disease Molecular Diagnostics Market Report

Infectious Disease Molecular Diagnostics Market Report Highlights

  • The reagent segment is expected to exhibit the fastest growth rate attributable to increased adoption

  • The growing geriatric population in Asian countries, such as Japan and China, with high untapped opportunities is expected to drive the market for infectious disease molecular diagnostics in the region during the forecast period

  • The In Situ Hybridization (ISH) segment is anticipated to witness the fastest growth rate owing to high sensitivity and lower complexity

  • The high growth rate of the market for infectious disease molecular diagnostics in the Asia Pacific can be attributed to increased access to healthcare in the developing nations

Infectious Disease Molecular Diagnostics Market Segmentation

Grand View Research has segmented the global infectious disease molecular diagnostics market based on product, end use, technology, application, and region:

Infectious Disease Molecular Diagnostics Product Outlook (Revenue, USD Million, 2017 - 2028)

  • Instruments

  • Reagents

  • Services

Infectious Disease Molecular Diagnostics End-use Outlook (Revenue, USD Million, 2017 - 2028)

  • Hospitals

  • Clinics

  • Diagnostics Laboratories

  • Research Institutes

Infectious Disease Molecular Diagnostics Technology Outlook (Revenue, USD Million, 2017 - 2028)

  • Polymerase Chain Reaction (PCR)

    • PCR, by Type

      • Multiplex PCR

      • Other PCR

    • PCR, by Product

      • Instruments

      • Reagents

      • Services

  • In Situ Hybridization

    • Instruments

    • Reagents

    • Services

  • Isothermal Nucleic Acid Amplification Technology (INAAT)

    • Instruments

    • Reagents

    • Services

  • Chips and Microarrays

    • Instruments

    • Reagents

    • Services

  • Mass Spectrometry

    • Instruments

    • Reagents

    • Services

  • Sequencing

    • Instruments

    • Reagents

    • Services

  • Transcription Mediated Amplification

    • Instruments

    • Reagents

    • Services

  • Others

    • Instruments

    • Reagents

    • Services

Infectious Disease Molecular Diagnostics Application Outlook (Revenue, USD Million, 2017 - 2028)

  • Respiratory Diseases

  • Tuberculosis

  • Meningitis

  • Gastrointestinal Tract Infections

  • HPV

  • Sexually Transmitted Infections

  • Sepsis

  • Drug Resistance Diseases

  • Other Infectious Diseases

Respiratory Diseases Outlook (Revenue, USD Million, 2017 - 2028)

  • Respiratory Diseases, By Product (Revenue, USD Million, 2017 - 2028)

    • Instruments

    • Reagents

    • Services

  • Respiratory Diseases, By End Use (Revenue, USD Million, 2017 - 2028)

    • Hospitals

    • Clinics

    • Diagnostics Laboratories

    • Research Institutes

  • Respiratory Diseases, By Technology, (Number of Tests Performed from 2017 - 2028 in Million) (Revenue, USD Million, 2017 - 2028)

    • Polymerase chain reaction (PCR)

    • In Situ Hybridization

    • Isothermal Nucleic Acid Amplification Technology (INAAT)

    • Chips and Microarrays

    • Mass Spectrometry

    • Sequencing

    • Transcription Mediated Amplification

    • Others

Tuberculosis Outlook (Revenue, USD Million, 2017 - 2028)

  • Tuberculosis, By Product (Revenue, USD Million, 2017 - 2028)

    • Instruments

    • Reagents

    • Services

  • Tuberculosis, By End Use (Revenue, USD Million, 2017 - 2028)

    • Hospitals

    • Clinics

    • Diagnostics Laboratories

    • Research Institutes

  • Tuberculosis, By Technology, (Number of Tests Performed from 2017 - 2028 in Million) (Revenue, USD Million, 2017 - 2028)

    • Polymerase chain reaction (PCR)

    • In Situ Hybridization

    • Isothermal Nucleic Acid Amplification Technology (INAAT)

    • Chips and Microarrays

    • Mass Spectrometry

    • Sequencing

    • Transcription Mediated Amplification

    • Others

Meningitis Outlook (Revenue, USD Million, 2017 - 2028)

  • Meningitis, By Product (Revenue, USD Million, 2017 - 2028)

    • Instruments

    • Reagents

    • Services

  • Meningitis, By End Use (Revenue, USD Million, 2017 - 2028)

    • Hospitals

    • Clinics

    • Diagnostics Laboratories

    • Research Institutes

  • Meningitis, By Technology, (Number of Tests Performed from 2017 - 2028 in Million) (Revenue, USD Million, 2017 - 2028)

    • Polymerase chain reaction (PCR)

    • In Situ Hybridization

    • Isothermal Nucleic Acid Amplification Technology (INAAT)

    • Chips and Microarrays

    • Mass Spectrometry

    • Sequencing

    • Transcription Mediated Amplification

    • Others

Gastrointestinal Tract Infections Outlook (Revenue, USD Million, 2017 - 2028)

  • Gastrointestinal Tract Infections, By Product (Revenue, USD Million, 2017 - 2028)

    • Instruments

    • Reagents

    • Services

  • Gastrointestinal Tract Infections, By End Use (Revenue, USD Million, 2017 - 2028)

    • Hospitals

    • Clinics

    • Diagnostics Laboratories

    • Research Institutes

  • Gastrointestinal Tract Infections, By Technology, (Number of Tests Performed from 2017 - 2028 in Million) (Revenue, USD Million, 2017 - 2028)

    • Polymerase chain reaction (PCR)

    • In Situ Hybridization

    • Isothermal Nucleic Acid Amplification Technology (INAAT)

    • Chips and Microarrays

    • Mass Spectrometry

    • Sequencing

    • Transcription Mediated Amplification

    • Others

HPV Outlook (Revenue, USD Million, 2017 - 2028)

  • HPV, By Product (Revenue, USD Million, 2017 - 2028)

    • Instruments

    • Reagents

    • Services

  • HPV, By End Use (Revenue, USD Million, 2017 - 2028)

    • Hospitals

    • Clinics

    • Diagnostics Laboratories

    • Research Institutes

  • HPV, By Technology, (Number of Tests Performed from 2017 - 2028 in Million) (Revenue, USD Million, 2017 - 2028)

    • Polymerase chain reaction (PCR)

    • In Situ Hybridization

    • Isothermal Nucleic Acid Amplification Technology (INAAT)

    • Chips and Microarrays

    • Mass Spectrometry

    • Sequencing

    • Transcription Mediated Amplification

    • Others

Sexually Transmitted Infections Outlook (Revenue, USD Million, 2017 - 2028)

  • Sexually Transmitted Infections, By Product (Revenue, USD Million, 2017 - 2028)

    • Instruments

    • Reagents

    • Services

  • Sexually Transmitted Infections, By End Use (Revenue, USD Million, 2017 - 2028)

    • Hospitals

    • Clinics

    • Diagnostics Laboratories

    • Research Institutes

  • Sexually Transmitted Infections, By Technology, (Number of Tests Performed from 2017 - 2028 in Million) (Revenue, USD Million, 2017 - 2028)

    • Polymerase chain reaction (PCR)

    • In Situ Hybridization

    • Isothermal Nucleic Acid Amplification Technology (INAAT)

    • Chips and Microarrays

    • Mass Spectrometry

    • Sequencing

    • Transcription Mediated Amplification

    • Others

Sepsis Outlook (Revenue, USD Million, 2017 - 2028)

  • Sepsis, By Product (Revenue, USD Million, 2017 - 2028)

    • Instruments

    • Reagents

    • Services

  • Sepsis, By End Use (Revenue, USD Million, 2017 - 2028)

    • Hospitals

    • Clinics

    • Diagnostics Laboratories

    • Research Institutes

  • Sepsis, By Technology, (Number of Tests Performed from 2017 - 2028 in Million) (Revenue, USD Million, 2017 - 2028)

    • Polymerase chain reaction (PCR)

    • In Situ Hybridization

    • Isothermal Nucleic Acid Amplification Technology (INAAT)

    • Chips and Microarrays

    • Mass Spectrometry

    • Sequencing

    • Transcription Mediated Amplification

    • Others

Drug Resistance Disease Outlook (Revenue, USD Million, 2017 - 2028)

  • Drug Resistance Disease, By Product (Revenue, USD Million, 2017 - 2028)

    • Instruments

    • Reagents

    • Services

  • Drug Resistance Disease, By End Use (Revenue, USD Million, 2017 - 2028)

    • Hospitals

    • Clinics

    • Diagnostics Laboratories

    • Research Institutes

  • Drug Resistance Disease, By Technology, (Number of Tests Performed from 2017 - 2028 in Million) (Revenue, USD Million, 2017 - 2028)

    • Polymerase chain reaction (PCR)

    • In Situ Hybridization

    • Isothermal Nucleic Acid Amplification Technology (INAAT)

    • Chips and Microarrays

    • Mass Spectrometry

    • Sequencing

    • Transcription Mediated Amplification

    • Others

Infectious Disease Molecular Diagnostics Regional Outlook (Revenue, USD Million, 2017 - 2028)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

List of Key Players of Infectious Disease Molecular Diagnostics Market

  • Abbott

  • Becton, Dickinson and Company

  • bioMérieux SA

  • Bio-Rad Laboratories, Inc.

  • Agilent Technologies, Inc.

  • Danaher Corporation

  • Hologic, Inc. (Gen-Probe)

  • Illumina, Inc.

  • Grifols S.A.

  • Qiagen

  • F. Hoffmann-La Roche Ltd

  • Siemens Healthineers AG

  • Sysmex Corporation

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.